Clinical Professor of Medicine, Department of Medicine and Section of Infectious Disease, University of Oklahoma Health Sciences Center and Mercy Health Center, 4205 McAuley Boulevard, Suite 400, Oklahoma City, OK 73120
Abortive Headache Therapy With Intramuscular Dihydroergotamine
Article first published online: 19 MAY 2005
Headache: The Journal of Head and Face Pain
Volume 32, Issue 1, pages 18–20, January 1992
How to Cite
Saadah, H. A. (1992), Abortive Headache Therapy With Intramuscular Dihydroergotamine. Headache: The Journal of Head and Face Pain, 32: 18–20. doi: 10.1111/j.1526-4610.1992.hed3201018.x
- Issue published online: 19 MAY 2005
- Article first published online: 19 MAY 2005
- Accepted for Publication: September 10, 1991.
- Cited By
- resistant headaches;
- intramuscular dihydroergotamine mesylat
During a six month period, intramuscular dihydroergotamine mesylate (1 mg.) was given to 43 patients (75 headache episodes) who presented to the office after oral medications failed to abort their headaches. Headaches were successfully aborted in 71%, with most responses occurring between 30-minutes and 4-hours after injection. Side effects were common (61%) but not serious; sedation developed in 25%, nausea in 24%, transient worsening of headaches in 15%, body aches in 11%, diarrhea in 5%, and in 13%, headaches that were successfully aborted relapsed within 24 hours. Intramuscular dihydroergotamine, although under-used, is cost effective, practical, and well suited for busy medical offices. Its appropriate use can reduce the need for narcotic analgesics and emergency room visits.